Why the study?
Heart failure omics represent rapidly expanding fields of science that have not been integrated into a single body of work to support early diagnosis and better pathophysiological understanding.
This AHA scientific statement provides a comprehensive overview of the current state and future applications of 'omics' data for precision medicine in the prevention, diagnosis, and therapy of heart failure.
May guide omics integration into future HF precision strategies; leaves open validation before clinical adoption.
One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics- of heart failure represent rapidly expanding fields of science that have, to date, not been integrated into a single body of work. The goals of this statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.
No takes yet. Share an insight, caveat, or question.
Cresci et al. (2019) conducted a review in Heart failure. Omics and precision medicine was evaluated. The integration of omics data offers potential future applications for precision medicine in the prevention, diagnosis, and therapy of heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: